Table 1.
Group I CRL (cm) (1.4–3.6) 30–60 days | Group II CRL (cm) (4.5–7.2) 67–90 days | Group III CRL (cm) (8–19) 97–135 days | Group IV CRL (cm) (21–33) 142–191 days | Group V CRL (cm) (36–40) 205–235 days | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
E | LP-S | TM | S | E | LP-S | TM | S | E | LP-S | TM | S | E | LP-S | TM | S | E | LP-S | TM | S | |
NNE | − | − | − | − | − | + | + | − | − | ++ | ++ | − | − | +++ | +++ | − | − | +++ | +++ | − |
GFAP | − | − | − | − | − | + | + | + | − | + | + | + | − | ++ | ++ | + | − | +++ | +++ | ++ |
VIM | − | − | − | − | − | + | + | + | − | + | + | + | − | ++ | ++ | + | − | +++ | +++ | ++ |
VIP | − | − | − | − | − | − | − | − | − | − | − | − | − | ++ | ++ | + | − | ++ | ++ | ++ |
NPY | − | − | − | − | − | − | − | − | − | − | − | − | ++ | ++ | + | − | ++ | ++ | ++ |
−, Non immunoreactivity; +, low immunoreactivity; ++, moderate immunoreactivity; +++, high immunoreactivity.
E, epithelium; Lp-S, lamina propia-submucosa; T, tunica muscularis; S, serosa.